Teen Marijuana Use Doubles Risk of Psychosis and Bipolar Disorder in 463K Study
A landmark study of 463,000 teens found cannabis use doubles the risk of psychotic and bipolar disorders by young adulthood.
Summary
A major study tracking over 463,000 adolescents found that teens who used cannabis were roughly twice as likely to develop serious psychiatric disorders, including psychosis and bipolar disorder, by their mid-twenties. The research, published in JAMA Health Forum, drew on electronic health records from routine pediatric visits between 2016 and 2023. Critically, cannabis use typically preceded diagnoses by nearly two years, suggesting a temporal link rather than reverse causation. Even occasional use — not just heavy or dependent use — was associated with elevated risk. As THC potency in commercial products rises sharply, researchers are calling for urgent public health action targeting youth access and product strength.
Detailed Summary
Adolescent cannabis use has long raised concerns among researchers, but a sweeping new study provides some of the strongest evidence yet that teen marijuana use is associated with serious, lasting psychiatric harm. Published in JAMA Health Forum, the study tracked 463,396 adolescents aged 13 to 17 through age 26, making it one of the largest longitudinal investigations of its kind.
The central finding is striking: teens who reported using cannabis in the past year faced approximately double the risk of developing psychotic disorders and bipolar disorder compared to non-users. Elevated risks were also observed for depression and anxiety. Because cannabis use was recorded an average of 1.7 to 2.3 years before psychiatric diagnoses were made, the study strengthens the case for a directional relationship — cannabis exposure during brain development may be contributing to later mental illness, not merely co-occurring with it.
Conducted by researchers from Kaiser Permanente, UC San Francisco, UC Southern California, and the Public Health Institute, the study used electronic health records from routine pediatric screenings. Importantly, it examined any self-reported past-year cannabis use — not just heavy use or diagnosed cannabis use disorder — broadening its public health implications considerably.
Context matters here: cannabis potency has surged dramatically. Average THC concentrations in California flower now exceed 20%, and some concentrates top 95% THC — far beyond levels studied in earlier research. Meanwhile, over 10% of U.S. teens aged 12 to 17 report past-year use, with rates rising to 26% among twelfth graders.
For health-conscious adults with children or adolescents in their lives, this research underscores cannabis as a meaningful neurological risk during developmental years. Public health experts are calling for potency limits, restricted youth marketing, and treatment of adolescent cannabis use as a serious medical concern rather than a benign behavior.
Key Findings
- Teen cannabis use was associated with roughly double the risk of psychotic and bipolar disorders by age 26.
- Cannabis use preceded psychiatric diagnoses by an average of 1.7 to 2.3 years, suggesting a temporal causal link.
- Even any past-year cannabis use — not just heavy use — was linked to significantly elevated psychiatric risk.
- THC potency in commercial cannabis has surged, with some concentrates exceeding 95% THC, amplifying potential harms.
- Over 26% of U.S. twelfth graders report cannabis use, making this a widespread adolescent public health concern.
Methodology
This is a research summary based on a peer-reviewed study published in JAMA Health Forum, a credible high-impact journal. The study used longitudinal electronic health record data from 463,396 adolescents, providing strong observational evidence. Funding from the National Institute on Drug Abuse adds institutional credibility, though the article is a news summary and not the full primary paper.
Study Limitations
The study is observational and cannot definitively establish causation; confounding factors such as genetics and socioeconomic status may influence both cannabis use and psychiatric outcomes. Self-reported cannabis use may introduce measurement error. The article is a news summary — the full JAMA Health Forum paper should be consulted for adjusted odds ratios, confidence intervals, and full covariate analyses.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: